Právní předpis byl sestaven k datu 19.12.2013.
Zobrazené znění právního předpisu je účinné od 25.12.2012 do 19.12.2013.
97
XXXXXXX
Xxxxxxxxxxxx xxxxxxxxxxxx xxxx,
xxxxxx xx xxxx x xxxxxxxx xxxxxxx Xxxxxxxxxxxx zahraničních xxxx x. 58/2007 Xx. x. x., x. 46/2008 Sb. x. x. x x. 47/2012 Sb. m. x. x Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx
Xxxxxxxxxxxx xxxxxxxxxxxx věcí xxxxxxx, že dne 16. xxxxxxxxx 2011 xxxx generální ředitelkou XXXXXX xxxxxxxx schválení xxxxxx xxxxx Xxxxxxx X - Xxxxxxx xxxxxxxxxx látek x xxxxx - Mezinárodní xxxxxxxx Mezinárodní xxxxxx xxxxx dopingu xx xxxxxx.1)
X xxxxx xxxxxx Xxxxxxx X xxxxxxxx xxxxxxx Xxxxxxxxx Xxxxx xxxxxxxxx.
Xxxx xxxxx Xxxxxxx X xxxxxxxxx x platnost x souladu s xxxxxxx 34 xxxx. 3 Xxxxxx xxx 1. ledna 2012 x tímto xxxx xxxxxxxxx x xxxxxxxx x xxx Xxxxxx xxxxxxxxx. Dnem vstupu xxxxxx xxxxx Xxxxxxx X v xxxxxxxx xxxxxxxx xxxxxx xxxxx Xxxxxxx I Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx xxxxxx xx 1. ledna 2011 x xxxxxxxxx xxx č. 47/2012 Sb. m. s.
Xxxxxxxx xxxxx Xxxxxxx X x její xxxxxxx xx xxxxxxx xxxxxx xx xxxxxxxxx současně.
1) Xxxxxxxxxxx xxxxxx proti dopingu xx xxxxxx xxxxxxx xxx 19. října 2005 v Xxxxxx xxxx xxxxxxxxx pod č. 58/2007 Sb. m. s.
MEZINÁRODNÍ XXXXXX PROTI DOPINGU XX XXXXXX
Xxxxxxx X - Xxxxxx xxxxxxxxxx xxxxx a xxxxx - Xxxxxxxxxxx xxxxxxxx
Xxxxx, 1. xxxxx 2012
XXXXXX XXXXXXXXXX XXXXX X XXXXX DOPINGU XXX XXX 2012
XXXXXXX XXXXXXXXXXXXX KODEX
Xxxxxx xx 1. xxxxx 2012
Xxxxx xxxxxx 4.2.2 Světového xxxxxxxxxxxxxxx xxxxxx všechny Xxxxxxxx xxxxx budou považovány xx "Xxxxxxxxxx xxxxx" xxxxx xxxxx ze xxxxxx S1, X2, X4.4, S4.5 x X6(x) a Xxxxxxxxxx xxxxx X1, M2 x M3.
XXXXX X XXXXXX ZAKÁZANÉ XXXXX (XXX SOUTĚŽI X XXXX SOUTĚŽ) |
XXXXXXXX LÁTKY
X0. XXXXXXXXXXX XXXXX
Jakákoliv xxxxxxxxxxxxx látka, která xxxx xxxxxxxx v xxxxxxxxxxxxx xxxxxxx Xxxxxxx x není aktuálně xxxxxxxxx pro humánní xxxxxxxxxxxx použití xxxxxxxxxx xxxxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxx (xxxx. xxxxxx x xxxxxxxxxxxx xxxx xxxxxxxxx stadiu xxxxxxx xxxx po xxxxxxxx xxxxxxxxxx, xxxxxxxxxx xxxxx, xxxxxxxxxxx xxxx), je xxxxxxxx xxxxx.
S1. XXXXXXXXXX XXXXX
Xxxxxxxxxx xxxxx jsou xxxxxxxx.
1. ANDROGENNÍ XXXXXXXXXX XXXXXXXX (XXX):
(x) Xxxxxxxx* XXX, xxxxxxxxxx:
1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3β,17β-xxxx); 1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx); xxxxxxxxx (xxxx-4-xx-3β,17β-xxxx); xxxxxxxxxx; xxxxxxxx; xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx); danazol (17α-ethynyl-17β-hydroxyandrost-4-eno[2,3-d]isoxazol); xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17β-xx); xxxxxxxxxxx; xxxxxxxxxxxxx (19-xxx-17α-xxxxx-4-xx-17-xx); xxxxxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxx (17β-hydroxy-17α-methyl-5α-androstano[2,3-c]-furazan); xxxxxxxxx; 4-xxxxxxxxxxxxxxxxxx (4,17β-xxxxxxxxxxxxxxxx-4-xx-3-xx); xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx; mesterolon; xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx (2α, 17α-xxxxxxxx-5α-xxxxxxxxx-3-xx-17β-xx); xxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9-xxxx-3-xx); xxxxxx-1-xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx); methyltestosteron; xxxxxxxxxx (xxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx); miboleron; xxxxxxxxx; 19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx); xxxxxxxxxx; xxxxxxxxxxxxxx; xxxxxxxxxxxx; xxxxxxxx; oxandrolon; oxymesteron; xxxxxxxxxx; prostanozol (17β-hydroxy-5α-androstano [3,2-x]xxxxxxx); xxxxxxxxx; xxxxxxxxxx; xxxxxxxxx; 1-testosteron (17β-xxxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxx (18α-xxxx-xxxxxx-4,9,11-xxxxx-17β-xx-3-xx); xxxxxxxxx x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx.
(b) Xxxxxxxxx** XXX, pokud xxxx podány exogenně:
Xxxxxxxxxxxxx (xxxxxxx-5-xx-3β,17β-xxxx), androstendion (xxxxxxx-4-xx-3,17-xxxx), xxxxxxxxxxxxxxxxxx, prasteron (xxxxxxxxxxxxxxxxxxxxx, XXXX), xxxxxxxxxxx x jejich xxxxxxxxxx x xxxxxxx, xxx xx s omezením xxxxx na xx:
5α-xxxxxxxxx-3α,17α-xxxx | 5-androstendion (androst-5-en-3,17-dion) |
5α-xxxxxxxxx-3α,17β-xxxx | |
5α-xxxxxxxxx-3β,17α-xxxx | xxx-xxxxxxxxxxxxxxxxxx |
5α-androstan-3β,17β-diol | xxxxxxxxxxxxxx |
xxxxxxx-4-xx-3α,17α-xxxx | 3α-hydroxy-5αandrostan-17-on |
xxxxxxx-4-xx-3α,17β-xxxx | 3β-xxxxxxx-5αxxxxxxxxx-17-xx |
androst-5-en-3β,17α-diol | 7α-xxxxxxx-XXXX |
xxxxxxx-5-xx-3α,17α-xxxx | 7β-hydroxy-DHEA |
xxxxxxx-5-xx-3α,17β-xxxX | 7-xxxx-XXXX |
xxxxxxx-5-xx-3β,17α-xxxx | 19-norandrosteron |
4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3β,17β-xxxx) | 19-noretiocholanolon |
2. Xxxxxxx anabolické xxxxx, xxxxxxxxxx:
Xxxxxxxxxxx, xxxxxxxxxx modulátory xxxxxxxxxxxxx xxxxxxxxx (XXXX), xxxxxxx, xxxxxxx, zilpaterol, xxx xx x omezením xxxxx xx ně.
Xxx xxxxx xxxxxxx xxxx sekce: * "xxxxxxxx" se xxxxxxxx x xxxxx, xxxxxx xxxx xxxx xxxxxxxx xxxxxxx produkovat xxxxxxxxx. ** "xxxxxxxxx " xx vztahuje x xxxxx, xxxxxx xxxx xxxx xxxxxxxxxx xxxxxxxxx. |
S2. XXXXXXXXX XXXXXXX, RŮSTOVÉ XXXXXXX X XXXXXXXX XXXXX
Xxxxxxxxxxx xxxxx x xxxxxx xxxxxxxxxx faktory xxxx xxxxxxxx:
1. Xxxxx xxxxxxxxxxx xxxxxxxxxxx (xxxx. erytropoetin (EPO), xxxxxxxxxxx (dEPO), xxxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxxxxx (XXX), methoxypolyethylenglykol-epoetin beta (XXXX), peginesatid /Hematide/);
2. Xxxxxxxxxxxxxxxxxx (XX) x Xxxxxxxxxxxx xxxxxx (XX) x xxxx;
3. Insuliny;
4. Xxxxxxxxxxxxxx;
5. Růstový xxxxxx (XX), xxxxxxxxxxxxx xxxxxxx xxxxxxx (XXXx), xxxxxxxxxxxx xxxxxxx faktor (XXX), xxxxxxxx xxxxxxx xxxxxxx xxxxxx-1 (XXX-1), xxxxxxxxxx xxxxxxx xxxxxxx (XXX), xxxxxxx xxxxxx xxxxxxxx x xxxxxxxx xxxxxxxx (XXXX) x xxxxxxxxxx-xxxxxxxxxxxx růstový xxxxxx (XXXX), xxxxxx jako xxxxxxxxx jiné růstové xxxxxxx ovlivňující xxxxxxx xxxx degradaci xxxxxxxx xxxxx, šlach x xxxxxx, krevní xxxxxxxx, xxxxxxx energie, xxxxxxxxxxxxx xxxxxxxx nebo ovlivňující xxxx xxxxxxxxx xxxxxx;
x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky.
X3. XXXX2- XXXXXXXX
Všichni xxxx-2 agonisté (xxxxxx xxxx xxxxxxxxxx xxxxxxxxx xxxxxxx) xxxx xxxxxxxx xxxxx xxxxxxxxxxx (maximálně 1600 mikrogramů xx 24 hodin), formoterolu (xxxxxxxxx 36 xxxxxxxxxx xx 24 xxxxx) x xxxxxxxxxxx xxxxx xxxx xxxxxx x xxxxxxxx x xxxxxxx x xxxxxxxxxxx léčebným xxxxxxx xxxxxxx.
Xxxxxxxxxx xxxxxxxxxxx x xxxx x koncentraci xxxxx xxx 1000 xx/xx x přítomnost xxxxxxxxxxx x xxxx x xxxxxxxxxxx xxxxx xxx 30 xx/xx xxxxxx xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxxx xxxxxxx, ale xxxx xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxx xxxxx, xxxxx sportovec neprokáže xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxx, xx xxxxxxxxxx xxxxxxxx xxx xxxxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxxxxx dávky xxxxx xxx xxxx xxxxxxx maximum.
S4. XXXXXXXXX X METABOLICKÉ XXXXXXXXXX
Xxxxxxxx je xxxxxxxxxxx:
1. Xxxxxxxxxx xxxxxxxx, zahrnující:
Aminoglutethimid, xxxxxxxxxx, xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (xxxxxxxxxxxxxxxxx), 4-xxxxxxxxx-3,6,17-xxxxx (6-oxo),exemestan, xxxxxxxxx, xxxxxxxx, testolacton, ale xx s xxxxxxxx xxxxx na ně.
2. Xxxxxxxxxx modulátory xxxxxxxxxxxxx xxxxxxxxx (XXXX), xxxxxxxxxx:
Raloxifen, xxxxxxxxx, xxxxxxxxx, ale xx x xxxxxxxx xxxxx xx xx.
3. Xxxxxxx xxxxxxxxxxxxxx xxxxx xxxxxxxxxx:
Cyklofenil, xxxxxxxxxxx, xxxxxxxx, xxx ne x xxxxxxxx pouze xx ně.
4. Xxxxx xxxxxxxxxxxx funkce xxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxx, ale xx x xxxxxxxx xxxxx xx xx.
5. Xxxxxxxxxxx xxxxxxxxxx: Xxxxxxxx xxxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxx /Xxxxxxxxxx Xxxxxxxxxxxx Xxxxxxxxx Xxxxxxxx δ (XXXXδ) xxxxxxxx/ (xxxx. XX 1516) x Xxxxxxxx xxxxxxxxxxxxxxx xxx xxxxxxxxxx AMP x součinnosti s XXXX xxxxx /XXXXδ-XXX-xxxxxxxxx xxxxxxx xxxxxx (AMPK) xxxx xxxxxxxx/ (xxxx. XXXXX)
X5. XXXXXXXXX X XXXXXXX MASKOVACÍ XXXXX
Xxxxxxxxx xxxxx xxxx xxxxxxxx. Xxxxxxxx:
Xxxxxxxxx, desmopressin, xxxxxxxxxxxxxxx (xxxx. glycerol, nitrožilní xxxxxx xxxxxxxx, xxxxxxxx, xxxxxxxxxxxxxxxxxx x mannitolu), xxxxxxxxxx x xxxxx xxxxx x xxxxxxxxx xxxxxxxxxxxx účinky. Lokální xxxxxxxx xxxxxxxxxxxx xxx xxxxx anestézi xxxx xxxxxxxx.
Diuretika xxxxxxxx:
Xxxxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx, indapamid, xxxxxxxx, kyselina xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxx (xxxx. bendroflumethiazid, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx), xxxxxxxxxx x xxxxx látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx (kromě xxxxxxxxxxxx, xxxxxxxxx x xxxxxxxxx xxxxxx xxxxxxxxxxx x xxxxxxxxxxxx, které xxxxxx xxxxxxxx).
Xxx použití (Xxx Xxxxxxx, případně Xxxx Xxxxxx) jakéhokoliv xxxxxxxx xxxxx se xxxxxxxxxx prahovým limitem (xx. xxxxxxxxxx, salbutamol, xxxxxx, xxxxx, efedrin, xxxxxxxxxxxx a xxxxxxxxxxxxx) xx spojení x xxxxxxxxxx xxxx jinou xxxxxxxxx xxxxxx xx xxxxxxxxxx xxxxxxx specifické Xxxxxxxxxxxx výjimky na xxxx xxxxx navíc x xx, která xxx xxxx udělena xx xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxx.
XXXXXXXX XXXXXX
X1. XXXXXXXXX XXXXXXX XXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
1. Xxxxxx xxxxxx, xxxxxx xxxxxxx autologní, xxxxxxxxx nebo xxxxxxxxxxx xxxx nebo xxxxxxxxx xxxxxxx x xxx xxxxxxxxx produktů xxxxxxxxxxx xxxxxx.
2. Umělé xxxxxxxxx xxxxxxxx, xxxxxxx xxxx xxxxxxx kyslíku, xxxxxxxxxx modifikované xxxxxxxxxxxxx xxxxxxxx (např.krevní xxxxxxxx xxxxxxxx xx hemoglobinu, xxxxxxxxxxxxxxxxxx hemoglobiny), xxxxxxxxxxxxxxxxxxx x xxxxxxxxxxx (XXX13), xxx xx x xxxxxxxx xxxxx xx xx. Xxxxxxxx xxxxxxx xxxxxxxx není.
X2. XXXXXXXX X XXXXXXXXX XXXXXXXXXX
Zakázané xx xxxxxxxxxxx:
1. Podvádění, xxxx xxxxx x xxxxxx, xx xxxxxx xxxxxxx xxxxxxxxx x xxxxxxxx Vzorků odebraných xxx Xxxxxxxxx kontrole xx xxxxxxxx. Xx xxxxxxxx záměnu x/xxxx xxxxxx (xxxx. xxxxxxxxxx) xxxx, xxx xx x xxxxxxxx xxxxx xx xx.
2. Xxxxxxxxxx infuze x/xxxx xxxxxxx více xxx 50 xx xx 6 hodin xxxx xxxxxxxx xxxxx xxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxx nemocničních zákroků xxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxx.
3. Postupný xxxxx, manipulace a xxxxxxxxx xxxxxxxxxxx množství xxxx xxxx xx xxxxxxxxx systému je xxxxxxxx.
M3. GENOVÝ XXXXXX
Z důvodu xxxxxxxxxx xx xxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxx následující:
1. Xxxxxxxx nukleových xxxxxxx xxxx xxxxxx xxxxxxxx;
2. Xxxxxxx normálních xxxx geneticky xxxxxxxxxxxxxx xxxxx;
LÁTKY X METODY ZAKÁZANÉ XXX XXXXXXX |
Xxxxx xxxxxxxxx SO xx X5 x X1 až M3 xxxxxxxxx xxxx jsou Xxx Xxxxxxx zakázané x xxxxxxxxxxx xxxxxxx:
XXXXXXXX LÁTKY
S6. XXXXXXXXXXX
Xxxxxxx xxxxxxxxxxx (xxxxxx xxxx xxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxx) xxxx xxxxxxxx, x xxxxxxxx xxxxxxxx imidazoiu x případě xxxxxx xxxxxxxx xxxxxxx x xxxxxxxxxxx zahrnutých xx Xxxxxxxxxxxxxx xxxxxxxx xxx xxx 2012*.
Stimulancia xxxxxxxx:
(x) Xxxxxxxxxxxx xxxxxxxxxxx:
Adrafinil, xxxxxxxxxx, xxxxxxxxxxx, amfetamin, xxxxxxxxxx, xxxxxxxxxx, benzfetamin, xxxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxx, fendimetrazin, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, 4-xxxxxxxxxxxxxx (xxxxxxxx), xxxxxxxxxx, xxxxxxxxxxx, xxxxxx, kropropamid, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx (x-), methylendioxyamfetamin, xxxxxxxxxxxxxxxxxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxx, x-xxxxxxxxxxxxxxx, prenylamin, prolintan.
Xxxxxxxxxxxx, které není xxxxxxxx xxxxxxx x xxxxx odstavci, je Xxxxxxxxxxx xxxxxx.
(x) Xxxxxxxxxx xxxxxxxxxxx (příklady):
Xxxxxxxxx**, katin***, efedrin****, xxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, heptaminol, xxxxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxx****, xxxxxxxxxxxxx, xxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxx), niketamid, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxxxxxxxx, xxxxxxx, pentetrazol, xxxxxxxxxxxxxx, xxxxxxxxxxxxx*****xxxxxxxxx, sibutramin, xxxxxxxxx, xxxxxxxxxxxxx x další xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx biologickými xxxxxx.
* Následující xxxxx xxxxxxxx do Monitorovacího xxxxxxxx 2012 (bupropion, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, kofein, xxxxxxx, pipradrol, synefrin) xxxxxx považovány za Xxxxxxxx xxxxx.
** Xxxxxxx podání xxxxxxxxxx (xxxx. xxxxx, xxxx xxxxxxxx) nebo xxxx xxxxxx xxxxxxxx x xxxxxxxxx anestetiky xxxx xxxxxxxx.
*** Xxxxx xx zakázaný xxxxx xxx xxxxxxxxxxx vyšší xxx 5 mikrogramů x 1 xx xxxx.
**** Xxxxxxx x xxxxxxxxxxxxx xxxx xxxxxxxx xxx koncentraci xxxxx než 10 xxxxxxxxxx v 1 xx xxxx.
***** Xxxxxxxxxxxxx xx zakázán, xxxxx xxxx xxxxxxxxxxx x xxxx xx xxxxx xxx 150 xxxxxxxxxx na mililitr
X7. XXXXXXXXX
Xxxxxxxx xx následujíci:
Buprenorfin, xxxxxxxxxxxxx, xxxxxxxxx(xxxxxx), xxxxxxxx x xxxx xxxxxxxx, xxxxxxxxxxx, metadon, xxxxxx, xxxxxxxx, xxxxxxxxx, pentazocin, xxxxxxx.
S8. XXXXXXXXXXX
Xxxxxxxx (xxxx. hašiš, xxxxxx x xxxxxxxxx) xxxx xxxxxxxxxx delta9tetrahydrokanabinol (XXX) a xxxxxxxxxxxxxx (xxxx. "Spice" /xxxxxxxxxx XXX018, XXX073/ x XX-210) xxxx xxxxxxxx.
X9. XXXXXXXXXXXXXXXXXXXX
Xxxxxxx xxxxxxxxxxxxxxxxxxxx podávané xxxxxx, xxxxxxxx, nitrožilní xxxx xxxxxxxxxxxxx aplikací xxxx xxxxxxxx.
XXXXX XXXXXXXX V URČITÝCH XXXXXXXX |
P1. XXXXXXX
Alkohol (etanol) xx xxxxxxxx xxxxx Xxx Xxxxxxx v xxxxxxxxxxxxx xxxxxxxx. Xxxxxxx xx xxxx xxxxxxxx xxxxxxxx zkouškou a/nebo xxxxxxxx xxxx. Prahová xxxxxxx xxx xxxxxxxx xxxxxxxxxxx xxxxxxxx (hematologická xxxxxxx) xx 0.10 x/x.
∙ Automobilový xxxxx (FIA)
∙ Xxxxxx (XXX)
∙ Xxxxxxx xxxxxx x xxxxxxxxxxxx(XXX)
∙ Xxxxxxxxxxx (XXXX)
∙ Xxxxxxxxxxx xxxxx (XXX)
∙ Xxxxx motorismus (UIM)
X2. BETA-BLOKÁTORY
Xxxxx xxxx xxxxx xxxxxx, xxxx-xxxxxxxxx xxxx xxxxxxxx xxxxx Při Xxxxxxx x xxxxxxxxxxxxx xxxxxxxx.
∙ Xxxxxxxxxxxx xxxxx (XXX)
∙ Xxxxxxxx (xxxxxxx xxxxxxxxxx) (WCBS)
∙ Xxxxx (FMB)
∙ Xxxx (IGF)
∙ Xxxxxxx x xxxxxxx (XXX)
∙ Xxxxxxx xxxxxx x xxxxxxxxxxxx (FAI)
∙ Xxxxxxxxxxx (XXXX, XXX) (xxxxxxxx xxxx Xxxx xxxxxx)
∙ Xxxxxxxx (XXX) - skoky xx xxxxxx x xxxxxxxxxxx xxxxxxxx-xxxxx x X-xxxxx,x xxxxxxxxx X-xxxxx x "xxx air"
∙ Petanque a xxxxxxx xxxxxx (XXXX)
∙ Xxxxxxx (XXXX, XXX) (zakázané xxxx Xxxx xxxxxx)
∙ Xxxxx (XXX)
∙ Xxxxx xxxxxxxxxx (XxX)
Xxxx-xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxx:
Xxxxxxxxxx, xxxxxxxxxx, xxxxxxxx, xxxxxxxxx, bisoprolol, xxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxx, karvedilol, xxxxxxxxx, xxxxxxxxxxx, metipranolol, xxxxxxxxxx, xxxxxxx, oxprenolol, xxxxxxxx, xxxxxxxxxxx, xxxxxxx, timolol, xxx ne x xxxxxxxx xxxxx na xx.
Xxxxxxxxx
Xxxxxx xxxxxxx č. 97/2012 Sb. x. x. xxxxx účinnosti xxxx 25.12.2012.
Xxxxxx xxxxxxx x. 97/2012 Xx. x. x. xxx zrušen xxxxxxx xxxxxxxxx č. 98/2013 Sb. m. s. x xxxxxxxxx xx 20.12.2013.
Xxxxx xxxxxxxxxxxx právních xxxxx xxxxxx xxxxxxxx xxxxxxxx x xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx xx xxxx xxxxxx derogační xxxxx xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx.